Case No.: MRL-NOP-21592-US-PCT

Page No.: 2

## **Listing of Claims**

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula (I):

$$\begin{array}{c|c}
R^2 & & R^a \\
Q^2 & & R^a \\
Q^3 & O & R^b \\
R^1 & & R^1
\end{array}$$

wherein

Y<sup>1</sup> is CH or N;

Q1 is selected from the group consisting of

- (1) -OH, and
- (2) NH<sub>2</sub>;

Q<sup>2</sup> and Q<sup>3</sup> independently selected from the group consisting of

- (1) hydrogen, and
- (2) halogen;

Ra is selected from the group consisting of

- (1) hydrogen,
- (2) C1-10 alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro, and
- (3) C<sub>3</sub> 8 eycloalkyl;

Rb is selected from the group consisting of

- (1) hydrogen, and
- $(2) C_{1-10}$  alkyl,
- (3)—C<sub>1-3</sub>-alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,

Case No.: MRL-NOP-21592-US-PCT

Page No.: 3

### (4) - C<sub>3</sub> & cycloalkyl,

wherein said cycloalkyl, alkyl and aryl are is unsubstituted or substituted with one or more

- (a) halo,
- (b) OH,
- (c) -CN.
- (d) O-C<sub>1-10-alkyl</sub>,
- (3) (5) –(CH<sub>2</sub>)<sub>n</sub>-NR<sup>c</sup>R<sup>d</sup> wherein R<sup>c</sup> and R<sup>d</sup> are selected from the group consisting of hydrogen and C<sub>1-10</sub> alkyl, and n is 2, 3 or 4, and
- (4) (6)  $-(CH_2)_n$ ,  $-O-R^e$ , wherein  $R^e$  is selected from the group consisting of
  - (a) C<sub>1-10</sub> alkyl,
  - (b) -C<sub>0-3</sub> alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,

wherein said alkyl and aryl are unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,

and n' is 1, 2, 3 or 4;

m is 1 or 2;

- R<sup>1</sup> is (1) aryl selected from the group consisting of phenyl and napthyl, or
  - (2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
  - (3) -C<sub>1-10</sub> alkyl, and
  - (4) -C<sub>3-8</sub> cycloalkyl,

wherein said aryl, heteroaryl, alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,

Case No.: MRL-NOP-21592-US-PCT

Page No.: 4

- (c) -CN,
- (d)  $-O-C_{1-10}$  alkyl,
- (e)  $-C_{1-10}$  alkyl,
- (f) -C3-8 cycloalkyl,
- (g) aryl selected from the group consisting of phenyl and napthyl, or
- (h) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

R<sup>2</sup> is selected from the group consisting of:

- (1)  $(R^4-SO_2)N(R^7)$ -, wherein  $R^4$  is
  - (a) -C<sub>1-10</sub> alkyl,
  - (b) -C3-8 cycloalkyl,

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv)  $-O-C_{1-10}$  alkyl,
- (v) -C<sub>1-10</sub> alkyl,
- (vi) -C3-8 cycloalkyl,
- (vii) aryl selected from the group consisting of phenyl and napthyl, or (viii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

and said aryl and heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D)  $-O-C_{1-10}$  alkyl,
- (E) -C3-8 cycloalkyl, or

Case No.: MRL-NOP-21592-US-PCT

Page No.: 5

## (F) -C<sub>1-10</sub> alkyl,

(c) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,
- (v) -C3-8 cycloalkyl, or
- (vi) -C<sub>1-10</sub> alkyl,

(d) – $(CH_2)_X$ -NR<sup>f</sup>Rg wherein R<sup>f</sup> and Rg are selected from the group consisting of hydrogen and  $C_{1-10}$  alkyl, and x is 0, 1, 2, 3 or 4, or R<sup>f</sup> and Rg, together with the nitrogen atom to which they are attached form the group



wherein y is 1 or 2,  $Y^5$  is  $-CHR^{21}$ , -O- or  $NR^{21}$ , wherein  $R^{21}$  is selected from the group consisting of;

- (i) hydrogen, and
- (ii)  $C_{1-10}$  alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C1-10 alkyl, or
- (E) -C<sub>3-8</sub> cycloalkyl;

Page No.: 6

R<sup>7</sup> is selected from the group consisting of

- (a) hydrogen, and
- (b)  $-C_{1-10}$  alkyl,
- (c) aryl selected from the group consisting of phenyl and napthyl, or
- (d) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl

wherein said alkyl, aryl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv)  $-O-C_{1-10}$  alkyl,
- (v) -C<sub>3-8</sub> cycloalkyl,
- (vi) aryl selected from the group consisting of phenyl and napthyl, or (vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl,
- (E) -C3-8 cycloalkyl, or
- (F) aryl selected from the group consisting of phenyl and napthyl;
- (e) -(CH<sub>2</sub>)<sub>V</sub>'-NRhRi wherein Rh and Ri are selected from the group consisting of hydrogen and  $C_{1-10}$  alkyl, and y' is 1, 2, 3 or 4, or or  $R^h$  and  $R^i$ , together with the nitrogen atom to which they are attached from the group

wherein y' is 1 or 2,  $Y^6$  is  $-CHR^{22}$ , -O- or  $NR^{22}$ , wherein  $R^{22}$  is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C1-10 alkyl, or
- (E) -C3-8 cycloalkyl,

or R<sup>4</sup> and R<sup>7</sup> are linked together to form the group

(a)

wherein z is 1, 2 or 3; or

(b)

wherein z is 1, 2 or 3

(2)

Page No.: 8

# wherein R8 is selected from the group consisting of

- (a) -CN,
- (b) hydrogen, and
- (c) tetrazolyl;

(3)

$$(2)$$
 CN wherein o is 1, 2, 3 or 4; and

(4)

$$Y^2$$

wherein Y<sup>2</sup> is -NH=CH- or -CH=NH-;

# R<sup>3</sup> is selected from the group consisting of

wherein Y<sup>3</sup> is CR<sup>6c</sup> or N;

 $R^5$  is  $C_{1\mbox{--}10}$  alkyl or  $C_{1\mbox{--}2}$  perfluoroalkyl;

R6a, R6b, and R6c are independently selected from the group consisting of:

(1) hydrogen,

Case No.: MRL-NOP-21592-US-PCT Page No.: 9

(2) halo,

- $(3) C_{1-10}$  alkyl,
- (4) OH,
- (5) CN,
- (6) -C3-8 cycloalkyl, and
- (7) -O-C<sub>1-10</sub> alkyl;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, and
- (3) -C3-8 cycloalkyl,

wherein said alkyl and cycloalkyl are unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) –CN,
- (d)  $-O-C_{1-10}$  alkyl,
- (e) -C3-8 cycloalkyl, and
- (f)  $-NRj R^k$  wherein Rj and  $R^k$  are  $C_{1-10}$  alkyl;

or R<sup>9</sup> and R<sup>10</sup> are joined together with the nitrogen atom to which they are attached to form

wherein w is 1, 2 or 3, and

R<sup>23</sup> is selected from the group consisting of

- (a) hydrogen,
- (b) -C<sub>1-10</sub> alkyl,
- (c) -C3-8 cycloalkyl,
- (d)  $-C_{2-10}$  alkenyl,
- (e)  $-C_{2-10}$  alkynyl,
- (f) -(CH<sub>2</sub>)<sub>p</sub>-phenyl,

Case No.: MRL-NOP-21592-US-PCT Page No.: 10

(g) -(CH<sub>2</sub>)<sub>p</sub>-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein p is 0 or 1, and

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -C<sub>1-10</sub> alkyl,
- (iii) -OH,
- (iv) –CN,
- (v)-C3-8 cycloalkyl, or
- (vi) -O-C<sub>1-10</sub> alkyl;

R<sup>11</sup> is selected from the group consisting of

- (1) CH -
- $(2) CH_2 -,$
- (3) O -, and
- $(4) NR^{17}$ -,

provided that when R<sup>11</sup> is -CH- the dotted line forms a bond and when R<sup>11</sup> is -CH<sub>2</sub>-,

-O- or -NR17- the dotted line is absent;

 $R^{17}$  is hydrogen or  $C_{1\text{--}10}$  alkyl, wherein said  $C_{1\text{--}10}$  alkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) –CN,
- (d) -C<sub>3-8</sub> cycloalkyl,
- (e)  $-0-C_{1-10}$  alkyl,
- (f)-(CH<sub>2</sub>)<sub>q</sub>-phenyl, wherein q is 1 or 2, and
- (g) -NR18R19, and

wherein R<sup>18</sup> and R<sup>19</sup> are independently selected from the group consisting of

- (i) hydrogen, or
- (ii) C<sub>1-10</sub> alkyl;

or R18 and R19, together with the nitrogen atom to which they are attached, form the group



wherein q' is 1 or 2, Y7 is -CHR24, -O- or NR24, wherein R24 is selected from the group consisting of;

- (a) hydrogen, and
- (b) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl, or
- (v) -C<sub>3-8</sub> cycloalkyl;

R<sup>26</sup> is selected from the group consisting of

- (1) hydrogen,
- (2)  $-C_{1-3}$  alkyl;

R12 is selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, wherein said alkyl is unsubstituted or substituted with one or more
  - (a) halo,
  - (b) -OH,
  - (c) –CN,
  - (d) -C3-8 cycloalkyl,
  - (e) -O-C<sub>1-10</sub> alkyl, or
  - $(f) NH_2$

Case No.: MRL-NOP-21592-US-PCT Page No.: 12

- (3) halo,
- (4) -C3-8 cycloalkyl,
- (5) aryl selected from the group consisting of phenyl and napthyl, and
- (6) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said aryl and heteroaryl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) CN,
- (d)  $-O-C_{1-10}$  alkyl,
- (e) -C<sub>3-8</sub> cycloalkyl, or
- (f) -C<sub>1-10</sub> alkyl;

R<sup>13</sup> is selected from the group consisting of

- (1) hydrogen,
- (2) C<sub>1-10</sub> alkyl, and
- (3) -C3-8 cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C<sub>3-8</sub> cycloalkyl,
- (e) -O-C<sub>1-10</sub> alkyl, and
- (f)  $-C_{1-10}$  alkyl;

R<sup>14</sup> is selected from the group consisting of

- (1) - $C_{1-10}$  alkyl, and
- (2) -C3-8 cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,

Case No.: MRL-NOP-21592-US-PCT

Page No.: 13

- (d) -C3-8 cycloalkyl,
- (e) -O-C<sub>1-10</sub> alkyl, or
- (f)  $-C_{1-10}$  alkyl;
- (3) -(CH<sub>2</sub>)<sub>v</sub>-NR<sup>15</sup>R<sup>16</sup>, wherein v is 2, 3 or 4, and wherein R<sup>15</sup> and R<sup>16</sup> are independently selected from the group consisting of
  - a) hydrogen, or
  - b) C<sub>1-10</sub> alkyl, wherein said C<sub>1-10</sub> alkyl is unsubstituted or substituted with one or more
    - (i) halo,
    - (ii) -OH,
    - (iii) -CN,
    - (iv) -C3-8 cycloalkyl, or
    - $(v) O C_{1-10}$  alkyl;

or R<sup>15</sup> and R<sup>16</sup>, together with the nitrogen atom to which they are attached, form the group



wherein s is 1 or 2,  $Y^4$  is -CHR<sup>24</sup>-, -O- or -NR<sup>24</sup>-, wherein R<sup>24</sup> is selected from the group consisting of

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) –CN,
- (D) -O-C<sub>1-10</sub> alkyl, or
- (E) -C<sub>3-8</sub> cycloalkyl,
- 4) -(CH<sub>2</sub>)<sub>r</sub>-phenyl, wherein r is 1, 2, 3, or 4, and

wherein said phenyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,

Case No.: MRL-NOP-21592-US-PCT

Page No.: 14

(c) -CN,

(d)  $-0-C_{1-10}$  alkyl,

(e) -C3-8 cycloalkyl, or

(f) -C<sub>1-10</sub> alkyl;

or R13 and R14, together with the nitrogen atom to which they are attached, form the group

wherein u is 1 or 2, Y8 is -CHR<sup>25</sup>-, -O- or -NR<sup>25</sup>-, wherein  $R^{25}$  is selected from the group consisting of

- (a) hydrogen,
- (b) C<sub>1-10</sub> alkyl,
- (c) -(CH2)t-phenyl,
- (d) -(CH<sub>2</sub>)<sub>t</sub>-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein t is 0 or 1, and

wherein said alkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -C<sub>1-10</sub> alkyl,
- (iii) -OH,
- (iv) -CN,
- (v) -C<sub>3-8</sub> cycloalkyl, or
- (vi) -O-C<sub>1-10</sub> alkyl;

or a pharmaceutically acceptable salt thereof.

2, 3. (Canceled)

Page No.: 15

(Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and R1 is selected from the group consisting of

- (1) phenyl, unsubstituted or substituted in one or two positions with halo; and
- (2) thienyl.
- (Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> is (R<sup>4</sup>-SO<sub>2</sub>)N(R<sup>7</sup>)-.
  - 6. (Canceled)
- (Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt 7. thereof, wherein R<sup>3</sup> is (1)

$$R^{6a}$$

$$R^{6b}$$

$$Y^{3}$$

$$R^{5}$$

$$Q$$

wherein Y<sup>3</sup> is CHR<sup>6c</sup>, R<sup>5</sup> is methyl, R<sup>6a</sup> and R<sup>6c</sup> are hydrogen and R<sup>6b</sup> is fluoro.

(Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt 8. thereof, wherein R<sup>3</sup> is (1)

Y<sup>3</sup> is N, R<sup>5</sup> is C<sub>1-2</sub> perfluoroalkyl, and R<sup>6a</sup> and R<sup>6b</sup> are hydrogen.

9. (Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is (2)

Case No.: MRL-NOP-21592-US-PCT

Page No.: 16

and  $R^9$  and  $R^{10}$  are each unsubstituted  $C_{1-10}$  alkyl, or  $R^9$  and  $R^{10}$  are joined together with the nitrogen atom to which they are attached to form

wherein w is 1;

 $R^{23}$  is  $-(CH_2)_p$ -phenyl or  $-(CH_2)_p$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein the phenyl and heteroaryl are unsubstituted or substituted with one or more chloro, and p is 0.

10. (Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is (3)

 $R^{11}$  is  $NR^{17}$  wherein  $R^{17}$  is hydrogen or  $C_{1-3}$  alkyl, and  $R^{12}$  is hydrogen or methyl.

11. (Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is (4)

Page No.: 17

 $R^{13}$  is hydrogen and  $R^{14}$  is -(CH<sub>2</sub>)<sub>v</sub>-NR<sup>15</sup>R<sup>16</sup> wherein v is 2 and R<sup>15</sup> and R<sup>16</sup> are each C<sub>1-10</sub> alkyl, which is unsubstituted or substituted with -OH, -CN or -OCH<sub>3</sub>.

12. (Previously Presented) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is (4)

wherein R13 and R14, together with the nitrogen atom to which they are attached, form the group

wherein u is 1 or 2, Y8 is -CHR25-, -O- or -NR25-.

## 13-15 (Canceled)

16. (Currently Amended) A compound of claim 1 which is selected from the group consisting of

H N H OH	D D D D D D D D D D D D D D D D D D D
N H N OH S	O H N H O H F
O S H O H F F	O S O H O H CI
N H O H	

O O O O O O O O O O O O O O O O O O O	
	O S O H N OH F
F N H OH	D H N OH

O S O H N O H	HO Y HO O H
	$ \begin{array}{c}                                     $
0, 5, 5, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	
N H NH <sub>2</sub>	H NH <sub>2</sub>

H NH2	O S H N O H F F
Z H OH F	H NH2  N H N H2  F
T H OH S	H NH2
H NH2	NC H NH2 N E Ph
NC H NH2 N Ph	NC H OH N = Ph

N OH OH	O NH OH
CN ONH ONH OH	CN OH NOH F
N NH N=N OH	F OH
F CN CN OH	CN FF F
CN CN OH OS S	N OH N OH

	,
	O Z HZ OH
	O N D H OH N D H
	N N N N N N N N N N N N N N N N N N N
	N N N N N N N N N N N N N N N N N N N
O NH2  NH2  NH2	NH <sub>2</sub>

NH <sub>2</sub>	
N N N N N N N N N N N N N N N N N N N	
NH <sub>2</sub>	
N NH <sub>2</sub>	O NH <sub>2</sub>

NH2 F	NH <sub>2</sub>
NH <sub>2</sub>	O S O O O O O O O O O O O O O O O O O O
NH2 NH2	
NH <sub>2</sub>	NH <sub>2</sub>

NH <sub>2</sub>	NH <sub>2</sub>
S S NH2	O NH2 CN
	O Z F
	NH <sub>2</sub>

NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub>	O NH <sub>2</sub> HN
O O O O O O O O O O O O O O O O O O O	NH <sub>2</sub>

HN HA	NH2 HN NH2 HN O NH2
H HN HZ	N N N N N N N N N N N N N N N N N N N
OS N NH2	O N N NH2
NH2 NH2 FF	ON O
O S CI H NH2 F	O O O O O O O O O O O O O O O O O O O

or a pharmaceutically acceptable salt thereof.

(Previously Presented) A pharmaceutical composition comprising a therapeutically 17. effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18-20 (Canceled).

#### 21. (New) A compound of formula (I):

$$\begin{array}{c|c}
R^2 & & R^a \\
Q^3 & O & R^b \\
R^1 & & R^1
\end{array}$$

wherein

Y<sup>1</sup> is CH or N;

Q1 is NH2;

Q<sup>2</sup> and Q<sup>3</sup> independently selected from the group consisting of

- (1) hydrogen, and
- (2) halogen;

Ra is selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro, and
- (3) -C3-8 cycloalkyl;

Rb is selected from the group consisting of

- (1) hydrogen, and
- $(2) C_{1-10}$  alkyl,
- (3) -C<sub>1-3</sub> alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,
- (4) -C<sub>3-8</sub> cycloalkyl,

wherein said cycloalkyl, alkyl and aryl are is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d)  $-O-C_{1-10}$  alkyl,
- (5) -(CH<sub>2</sub>)<sub>n</sub>-NR<sup>c</sup>R<sup>d</sup> wherein R<sup>c</sup> and R<sup>d</sup> are selected from the group consisting of hydrogen and C<sub>1-10</sub> alkyl, and n is 2, 3 or 4, and
- (6) -(CH<sub>2</sub>)<sub>n</sub>,-O-Re, wherein Re is selected from the group consisting of
  - (a) C<sub>1-10</sub> alkyl,
  - (b) -C<sub>0-3</sub> alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,

wherein said alkyl and aryl are unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C<sub>1-10</sub> alkyl,

and n' is 1, 2, 3 or 4;

m is 1 or 2;

- R1 is (1) aryl selected from the group consisting of phenyl and napthyl, or
  - (2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
  - (3) -C<sub>1-10</sub> alkyl, and
  - (4) -C<sub>3-8</sub> cycloalkyl,

wherein said aryl, heteroaryl, alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) –CN,
- (d)  $-O-C_{1-10}$  alkyl,

Case No.: MRL-NOP-21592-US-PCT Page No.: 36

- (e)  $-C_{1-10}$  alkyl,
- (f) -C3-8 cycloalkyl,
- (g) aryl selected from the group consisting of phenyl and napthyl, or
- (h) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

R<sup>2</sup> is selected from the group consisting of:

- (1)  $(R^4-SO_2)N(R^7)$ -, wherein  $R^4$  is
  - (a)  $-C_{1-10}$  alkyl,
  - (b) -C<sub>3-8</sub> cycloalkyl,

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv)  $-O-C_{1-10}$  alkyl,
- (v) -C<sub>1-10</sub> alkyl,
- (vi) -C<sub>3-8</sub> cycloalkyl,
- (vii) aryl selected from the group consisting of phenyl and napthyl, or (viii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

and said aryl and heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) –CN,
- (D)  $-0-C_{1-10}$  alkyl,
- (E) -C3-8 cycloalkyl, or
- (F) -C1-10 alkyl,

Case No.: MRL-NOP-21592-US-PCT Page No.: 37

(c) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

> wherein said heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv)  $-O-C_{1-10}$  alkyl,
- (v) -C3-8 cycloalkyl, or
- (vi) -C<sub>1-10</sub> alkyl,

(d) -(CH<sub>2</sub>)<sub>x</sub>-NRfRg wherein Rf and Rg are selected from the group consisting of hydrogen and C<sub>1-10</sub> alkyl, and x is 0, 1, 2, 3 or 4, or Rf and Rg, together with the nitrogen atom to which they are attached form the group



wherein y is 1 or 2, Y<sup>5</sup> is -CHR<sup>21</sup>, -O- or NR<sup>21</sup>, wherein R<sup>21</sup> is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl, or
- (E) -C3-8 cycloalkyl;

Case No.: MRL-NOP-21592-US-PCT Page No.: 38

## R<sup>7</sup> is selected from the group consisting of

- (a) hydrogen, and
- (b)  $-C_{1-10}$  alkyl,
- (c) aryl selected from the group consisting of phenyl and napthyl, or
- (d) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl

wherein said alkyl, aryl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv)  $-O-C_{1-10}$  alkyl,
- (v) -C3-8 cycloalkyl,
- (vi) aryl selected from the group consisting of phenyl and napthyl, or (vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl,
- (E) -C<sub>3-8</sub> cycloalkyl, or
- (F) aryl selected from the group consisting of phenyl and napthyl;
- (e) –(CH<sub>2</sub>)<sub>V</sub>'–NRhRi wherein Rh and Ri are selected from the group consisting of hydrogen and C<sub>1-10</sub> alkyl, and y' is 1, 2, 3 or 4, or or R<sup>h</sup> and R<sup>i</sup>, together with the nitrogen atom to which they are attached from the group



wherein y' is 1 or 2, Y6 is -CHR<sup>22</sup>, -O- or NR<sup>22</sup>, wherein R<sup>22</sup> is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D)  $-O-C_{1-10}$  alkyl, or
- (E) -C3-8 cycloalkyl,

or R4 and R7 are linked together to form the group

(a)

wherein z is 1, 2 or 3; or

(b)

wherein z is 1, 2 or 3

(2)

## wherein $R^8$ is selected from the group consisting of

- (a) -CN,
- (b) hydrogen, and
- (c) tetrazolyl;

(3)

$$(2)$$
 CN wherein o is 1, 2, 3 or 4; and

(4)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

wherein Y<sup>2</sup> is –NH=CH- or –CH=NH-;

## R<sup>3</sup> is selected from the group consisting of

wherein Y<sup>3</sup> is CR<sup>6c</sup> or N;

R<sup>5</sup> is C<sub>1-10</sub> alkyl or C<sub>1-2</sub> perfluoroalkyl;

R6a, R6b, and R6c are independently selected from the group consisting of:

(1) hydrogen,

Case No.: MRL-NOP-21592-US-PCT

Page No.: 41

(2) halo,

- $(3) C_{1-10}$  alkyl,
- (4) OH,
- (5) –CN,
- (6) -C3-8 cycloalkyl, and
- $(7) O C_{1-10}$  alkyl;

R9 and R10 are independently selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, and
- (3) -C<sub>3-8</sub> cycloalkyl,

wherein said alkyl and cycloalkyl are unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C<sub>1-10</sub> alkyl,
- (e) -C3-8 cycloalkyl, and
- (f) -NRj Rk wherein Rj and Rk are C<sub>1-10</sub> alkyl;

or  $R^9$  and  $R^{10}$  are joined together with the nitrogen atom to which they are attached to form

wherein w is 1, 2 or 3, and

R<sup>23</sup> is selected from the group consisting of

- (a) hydrogen,
- (b) -C<sub>1-10</sub> alkyl,
- (c) -C3-8 cycloalkyl,
- (d) -C2-10 alkenyl,
- (e) -C2-10 alkynyl,
- (f) -(CH2)p-phenyl,

Page No.: 42

(g) -(CH<sub>2</sub>)<sub>p</sub>-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein p is 0 or 1, and

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -C<sub>1-10</sub> alkyl,
- (iii) -OH,
- (iv) –CN,
- (v) -C<sub>3-8</sub> cycloalkyl, or
- (vi) -O-C<sub>1-10</sub> alkyl;

R<sup>11</sup> is selected from the group consisting of

- (1) CH -
- $(2) CH_2 -,$
- (3) O -, and
- $(4) NR^{17} -$

provided that when R<sup>11</sup> is -CH- the dotted line forms a bond and when R<sup>11</sup> is -CH<sub>2</sub>-,

-O- or -NR17- the dotted line is absent;

R<sup>17</sup> is hydrogen or C<sub>1-10</sub> alkyl, wherein said C<sub>1-10</sub> alkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C<sub>3-8</sub> cycloalkyl,
- (e)  $-O-C_{1-10}$  alkyl,
- (f) -(CH<sub>2</sub>)<sub>q</sub>-phenyl, wherein q is 1 or 2, and
- (g) -NR18R19, and

wherein R<sup>18</sup> and R<sup>19</sup> are independently selected from the group consisting of

- (i) hydrogen, or
- (ii) C<sub>1-10</sub> alkyl;

or R<sup>18</sup> and R<sup>19</sup>, together with the nitrogen atom to which they are attached, form the group



wherein q' is 1 or 2, Y<sup>7</sup> is -CHR<sup>24</sup>, -O- or NR<sup>24</sup>, wherein R<sup>24</sup> is selected from the group consisting of;

- (c) hydrogen, and
- (d) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C1-10 alkyl, or
- (v) -C<sub>3-8</sub> cycloalkyl;

R<sup>26</sup> is selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-3</sub> alkyl;

R12 is selected from the group consisting of

- (1) hydrogen,
- (2) -C<sub>1-10</sub> alkyl, wherein said alkyl is unsubstituted or substituted with one or more
  - (a) halo,
  - (b) -OH,
  - (c) -CN,
  - (d) -C<sub>3-8</sub> cycloalkyl,
  - (e) -O-C<sub>1-10</sub> alkyl, or
  - $(f) NH_2$

Case No.: MRL-NOP-21592-US-PCT Page No.: 44

- (3) halo,
- (4) -C<sub>3-8</sub> cycloalkyl,
- (5) aryl selected from the group consisting of phenyl and napthyl, and
- (6) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said aryl and heteroaryl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) –CN,
- (d)  $-0-C_{1-10}$  alkyl,
- (e) -C3-8 cycloalkyl, or
- (f)  $-C_{1-10}$  alkyl;

R<sup>13</sup> is selected from the group consisting of

- (1) hydrogen,
- (2) C<sub>1-10</sub> alkyl, and
- (3) -C<sub>3-8</sub> cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) –CN,
- (d) -C3-8 cycloalkyl,
- (e) -O-C<sub>1-10</sub> alkyl, and
- (f) -C<sub>1-10</sub> alkyl;

R<sup>14</sup> is selected from the group consisting of

- (1) -C<sub>1-10</sub> alkyl, and
- (2) -C3-8 cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,

Case No. MRL-NOP-21592-US-PCT

Page No.: 45

(d) -C<sub>3-8</sub> cycloalkyl,

- (e) -O-C<sub>1-10</sub> alkyl, or
- (f) -C<sub>1-10</sub> alkyl;
- (3) -(CH<sub>2</sub>)<sub>V</sub>-NR<sup>15</sup>R<sup>16</sup>, wherein v is 2, 3 or 4, and wherein R<sup>15</sup> and R<sup>16</sup> are independently selected from the group consisting of
  - a) hydrogen, or
  - b) C<sub>1-10</sub> alkyl, wherein said C<sub>1-10</sub> alkyl is unsubstituted or substituted with one or more
    - (i) halo,
    - (ii) -OH,
    - (iii) -CN,
    - (iv) -C3-8 cycloalkyl, or
    - (v) -O-C<sub>1-10</sub> alkyl;

or R<sup>15</sup> and R<sup>16</sup>, together with the nitrogen atom to which they are attached, form the group



wherein s is 1 or 2,  $Y^4$  is -CHR<sup>24</sup>-, -O- or -NR<sup>24</sup>-, wherein R<sup>24</sup> is selected from the group consisting of

- (i) hydrogen, and
- (ii) C<sub>1-10</sub> alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C<sub>1-10</sub> alkyl, or
- (E) -C<sub>3-8</sub> cycloalkyl,
- 4) -(CH<sub>2</sub>)<sub>r</sub>-phenyl, wherein r is 1, 2, 3, or 4, and

wherein said phenyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,

Case No.: MRL-NOP-21592-US-PCT

Page No.: 46

(c) -CN,

(d)  $-0-C_{1-10}$  alkyl,

(e) -C<sub>3-8</sub> cycloalkyl, or

(f) -C<sub>1-10</sub> alkyl;

or R13 and R14, together with the nitrogen atom to which they are attached, form the group

wherein u is 1 or 2, Y8 is -CHR<sup>25</sup>-, -O- or -NR<sup>25</sup>-, wherein R<sup>25</sup> is selected from the group consisting of

- (a) hydrogen,
- (b) C<sub>1-10</sub> alkyl,
- (c) -(CH2)t-phenyl,
- (d) -(CH2)t-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein t is 0 or 1, and

wherein said alkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -C<sub>1-10</sub> alkyl,
- (iii) -OH,
- (iv) -CN,
- (v) -C3-8 cycloalkyl, or
- (vi)  $-O-C_{1-10}$  alkyl;

or a pharmaceutically acceptable salt thereof.

Case No.: MRL-NOP-21592-US-PCT Page No.: 47

22. (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, wherein m is 1 and R<sup>1</sup> is selected from the group consisting of

- (1) phenyl, unsubstituted or substituted in one or two positions with halo; and
- (2) thienyl.
- 23. (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, wherein  $R^2$  is  $(R^4-SO_2)N(R^7)$ -.
- (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, 24. wherein  $R^3$  is (1)

$$\begin{array}{c}
R^{6a} \\
R^{6b} \stackrel{\text{II}}{\overset{\text{V}}{3}} \\
R^{5} O
\end{array}$$

wherein Y3 is CHR6c, R5 is methyl, R6a and R6c are hydrogen and R6b is fluoro.

25. (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, wherein  $R^3$  is (2)

and R<sup>9</sup> and R<sup>10</sup> are each unsubstituted C<sub>1-10</sub> alkyl, or R<sup>9</sup> and R<sup>10</sup> are joined together with the nitrogen atom to which they are attached to form attached to form

wherein w is 1;

Page No.: 48

R<sup>23</sup> is –(CH<sub>2</sub>)<sub>p</sub>-phenyl or –(CH<sub>2</sub>)<sub>p</sub>-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein the phenyl and heteroaryl are unsubstituted or substituted with one or more chloro, and p is 0.

26. (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, wherein  $\mathbb{R}^3$  is (3)

R<sup>11</sup> is NR<sup>17</sup> wherein R<sup>17</sup> is hydrogen or C<sub>1-3</sub> alkyl, and R<sup>12</sup> is hydrogen or methyl.

27. (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is (4)

 $R^{13}$  is hydrogen and  $R^{14}$  is  $-(CH_2)_v$ -NR<sup>15</sup>R<sup>16</sup> wherein v is 2 and R<sup>15</sup> and R<sup>16</sup> are each C<sub>1-10</sub> alkyl, which is unsubstituted or substituted with -OH, -CN or -OCH<sub>3</sub>.

28. (New) The compound of Claim 21, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is (4)

wherein R13 and R14, together with the nitrogen atom to which they are attached, form the group

wherein u is 1 or 2,  $Y^8$  is -CHR<sup>25</sup>-, -O- or -NR<sup>25</sup>-.

## A compound of claim 21, which is selected from the group consisting of 29. (New)

N. SO <sub>2</sub> Me  N H NH <sub>2</sub> N E	H NH2
N H NH <sub>2</sub>	DH2 PH2 PH2 PH2 PH2 PH3 PH3 PH3 PH3 PH3 PH3 PH3 PH3 PH3 PH3
H NH2	N H NH2
N H NH2	NC H NH <sub>2</sub> N D Ph

NC H NH2 N E Ph	NC H NH <sub>2</sub> N - Ph
NC H NH <sub>2</sub> N = Ph	NC H NH <sub>2</sub> N = Ph
MeO <sub>2</sub> S.  H N H NH <sub>2</sub> CF <sub>3</sub> O O Ph	MeO <sub>2</sub> S.  H N O O N S
NH NH <sub>2</sub>	NH <sub>2</sub>
NH NH <sub>2</sub>	NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub>

NH <sub>2</sub>	NH <sub>2</sub> F
NH NH <sub>2</sub> F	NH <sub>2</sub> F
NH <sub>2</sub> F	NH <sub>2</sub> F
ON SON NH2 F	NH <sub>2</sub> F

NH <sub>2</sub> F	NH <sub>2</sub>
NH NH <sub>2</sub>	NH <sub>2</sub> F  NH <sub>2</sub> F  NH <sub>2</sub> F
NH NH <sub>2</sub>	ON NH2
NH NH <sub>2</sub>	NH N

NH <sub>2</sub>	NH NH2
NH <sub>2</sub> F	NH <sub>2</sub> F  NH <sub>3</sub> NH  NH  NH  NH  NH  NH  NH  NH  NH  N
F N NH <sub>2</sub>	NH <sub>2</sub> F
NH <sub>2</sub> F  NH <sub>2</sub> F	NH <sub>2</sub> F

O NH <sub>2</sub> F	NH <sub>2</sub> O
NH <sub>2</sub> F	NH <sub>2</sub>
O S O NH <sub>2</sub> F F	NH <sub>2</sub> O N N N N N N N N N N N N N N N N N N
NH <sub>2</sub> NH NH O	NH <sub>2</sub> NH <sub>2</sub> O

NH <sub>2</sub> NH <sub>2</sub> O	NH <sub>2</sub> F
O S N NH <sub>2</sub> F	NH <sub>2</sub> F
NH <sub>2</sub>	NH <sub>2</sub>
OSC NH2 NH2 NH2	N N N N N N N N N N N N N N N N N N N

NH <sub>2</sub> NH <sub>2</sub>	O Z H2 H
NH <sub>2</sub>	O ZH <sub>2</sub>
NH NH2	NH <sub>2</sub> NH <sub>2</sub> F
NH <sub>2</sub>	NH <sub>2</sub> NH NH F

NH <sub>2</sub>	NH <sub>2</sub>
NH <sub>2</sub> NH F	NH <sub>2</sub>
NH2	NH <sub>2</sub> NH <sub>2</sub>
H NH <sub>2</sub> F F	NH <sub>2</sub>
NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub>	NH2 NH2 FF

NH NH2	NH <sub>2</sub> F F F F
OSON NH2	NH <sub>2</sub>
NH <sub>2</sub> F F F	ON SON H NH2 F
ON SON SON SON SON SON SON SON SON SON S	O O O O O O O O O O O O O O O O O O O

or a pharmaceutically acceptable salt thereof.

(New) A pharmaceutical composition comprising a therapeutically effective amount of 30. a compound of Claim 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.